Newsletter Oncology InnoSer

The application of bioluminescence imaging (BLI) in preclinical research studies offers quantitative, sensitive, longitudinal real-time data and can be applied in: 

  • Validation of cancer cell lines, helping to establish improved preclinical cancer mouse models. 
  • Syngeneic (rodent cell lines) and/or xenograft (human cell lines) tumour models, offering improved sensitivity to traditional calliper measurements in helping detect (early) tumour growth regression following drug treatment.  
  • Orthotopic tumour models, enabling assessment of tumour growth in a model with relevant tumour microenvironment in mouse models of colorectal cancer, lung cancer, glioblastoma etc., (Figure 1A and B).  
  • Metastatic tumour models, enabling the sensitive assessment and extent of metastasis in a various range of cancer types. 
  • Studies used to evaluate novel (immuno)therapies such as CAR-T cells, NK cells, checkpoint inhibition, combination and radiation therapies.  
  • Studies evaluating novel therapy’s mechanism of action complemented with immune cell profiling via flow cytometry.  
  • Studies aiming to assess novel delivery methods such as lipid nanoparticles (LNPs), exosomes, liposomes, etc., to obtain biodistribution, compound’s half-life and stability information (Figure 1C).  
  • Evaluation of (stem) cell therapies, offering valuable information on survival, functional behaviour and stability of implanted (stem) cells.   
Example uses of BLI in orthotopic tumor models or novel delivery agents

FIGURE 1. Application and most common uses of BLI in cancer research. (A) Evaluation of orthotopic tumour growth. Here shown are example images of orthotopic tumour model of colorectal carcinoma using the MC38-luc cell line. (B) Evaluation of orthotopic tumour growth. Here shown are example images of tumour progression in the breast cancer mouse model using the 4T1-luc cell line. (C) Evaluation of novel delivery methods. Following delivery of novel drug delivery vehicles such as LNPs, the BLI signal allows to discriminate the distribution between the liver and spleen, providing real-time biodistribution and delivery information of novel therapeutic agents over time 

All efficacy studies can be complemented with histopathology readouts with in-house expert pathologist evaluation. To help you fine tune your lead compound’s bioavailability, InnoSer has ample experience in carrying out PK/PD studies and analyses. 

Be the first to know – get this news straight to your inbox

InnoSer provides a variety of validated in vitro and in vivo screening tests for immunology and oncology. If you require additional information, feel free to reach out, and we will respond within a few days.

We provide a monthly update from our oncology labs containing scientific insights into our research services. To get news straight to your inbox please sign up here.